At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
Bio Pharma Dive
MARCH 22, 2023
Armed with a $50 million Series A round, the startup is building off of research from a lab run by protein engineering pioneer Jim Wells.
Let's personalize your content